ByTrending Posts
Could Merck and Daiichi Sankyo’s 48% Response Rate…
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine…
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Could Servier’s $450M Fragile X Acquisition Redefine Its…
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu…
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine…
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care…
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral…
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could the Medtronic–Abbott Partnership Shift the Future of…
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…
Could Medtronic’s Hugo™ Robotic System Redefine Hernia Surgery…
Key Highlights A Landmark Clinical Study for Robotic Hernia SurgeryMedtronic’s Enable Hernia Repair trial is the first Investigational…
Trending Posts
Latest Stories
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly…
Can Ianalumab Anchor Novartis’ Next Growth Cycle as Patent Pressures Mount?
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage…
Gallery
